METHODS

Study Design
This observational, prospective, multicenter study was conducted (during the period 
Population for Primary Endpoint Analysis
The population for the primary endpoint analysis (PEA) included all EAS patients plus patients who discontinued liraglutide treatment but remained in the study. The purpose of this pre-specified population was to prevent loss of data from patients who discontinued liraglutide before 2 years of follow-up.
Patient-Reported Outcomes Analysis Set
The population for the patient-reported outcomes set (PROAS) included all patients in the FAS who also filled in at least one item on the patient questionnaire at the inclusion visit and at least one follow-up visit. The DTSQs (status version) (satisfaction with treatment at each visit, which has a minimum score of zero and a maximum score of 36) and DTSQc (change version) (change in satisfaction with treatment between inclusion and 12 months, which has a minimum score of -18 and a maximum score of 18) were analyzed using the PROAS.
Change in satisfaction with treatment was measured at 12 months due to the high number of missing data, with regard to this parameter, at 24 months.
Missing Data
No replacement of missing data was planned as part of the analysis of the primary endpoint.
Statistical Analysis
Calculating the sample size was based on the expected accuracy for the confidence interval 
RESULTS
Patient Disposition
In total, 3590 patients with T2D were considered for inclusion. However, 438 patients were not included, mainly for the following reasons: patient refusal (36.0%), miscellaneous reasons (31.0%), well-controlled diabetes (11.0%), or issues with compliance or irregular follow-up in consultation (10.0%). In total, 1143 patients withdrew from the study early (before 2 years of follow-up)-41.0% were lost to follow-up or moved and 21.8% withdrew due to AEs. The distribution of patients during the study is shown in Fig. 1 . Fig. 1 Distribution of patients during the study. Asterisks some patients had thoroughly completed the 2 years of follow-up though the physician filled an end of study form out with a reason for withdrawal from study. These patients (20 in total) were included in the EAS population and counted as withdrawals from study. Double asterisks patients lost to follow-up or moved. AE adverse event, EAS effectiveness analysis set, FAS full analysis set, FPG fasting plasma glucose, PEA population for primary endpoint analysis, PROAS patient-reported outcomes analysis set
Baseline Characteristics
Baseline characteristics were collected from 3152 patients (FAS) enrolled in the EVIDENCE study and are shown in Table 1 
Secondary Endpoints
Evolution of Antidiabetic Treatment
The most common reasons for prescribing liraglutide were desire for improvement of glycemic and weight control ( Table 2 ). The evolution of antidiabetic treatment was analyzed using the EAS population (2029 patients). Liraglutide dose was initiated at 0.6 mg/day and, by 3 months, the percentage of patients prescribed 1.2 mg/day liraglutide had increased from 11.1% to 75.9%. Patients who demonstrated inadequate glycemic control on the 1.2 mg/day liraglutide dose were then transferred to the 1.8 mg/day dose. At the end of the study, 49.1% and 45.5% of patients received 1.2 mg/day or 1.8 mg/day of liraglutide, respectively (Fig. 2 ). However, due to concerns with tolerability of the higher doses or observed efficacy with the 0.6 mg/day dose, the remaining 5.4% of patients received Coronary disease, n (%) 364 (11.6)
Lower limb arteritis, n (%) 176 (5.6)
Other, n (%) 110 (3.5)
Clinical characteristics
Body weight (3151 patients analyzed)
Mean (±SD), kg 95.6 (±19.9) 0.6 mg/day liraglutide. Liraglutide was added to current antidiabetic therapy and, by the end of the study, there was a reduction in oral antidiabetic drug (OAD) monotherapy and an increase in the number of patients receiving more than three therapies in combination.
Throughout the study, rates of prescription of biguanides, sulfonylureas (SUs), glinides, and alpha-glucosidase inhibitors remained stable. In contrast, prescriptions of DPP-4 inhibitors and glitazones fell from baseline to end of study (40.1% to 9.7% and 14.1% to 3.0%, respectively) and those of insulin increased from baseline to end of study (12.9% to 24.0%) ( Table 3) . n number for subset, SD standard deviation a A patient may have been included in the study by a general practitioner but also managed by an endocrinologist b All historical medical events were registered on the basis of patient reporting or their medical record c Patients may have had more than one complication. Due to missing data, the % value relates to the number of patients analyzed within the FAS population for that particular characteristic and not the total FAS population DPP-4 dipeptidyl peptidase-4, EAS effectiveness analysis set, FAS full analysis set, n number for subset, SU Sulfonylurea a There were the same number of patients still remaining in both FAS and EAS populations at the end of the study; therefore, the percentages are the same in both populations. Values are expressed as n (%). Due to missing data, the % value relates to the number of patients analyzed within the FAS or EAS population for that particular time point and not the total FAS or EAS population by the DTSQc, was, on average, 10.71 (±6.10) (95.0% CI 10.39; 11.03).
Hypoglycemia
Hypoglycemic episodes were analyzed using the FAS population. The percentage of patients experiencing at least one hypoglycemic episode (in the 4 weeks preceding each visit) decreased during the study, from 7.4% at 3 months to 4.4% at end of study. Most episodes were minor, not requiring third-party intervention. Nine patients reported severe hypoglycemia during the 2-year study period. These patients were also being treated with either biguanides and SUs or insulin and glinides, and there was no correlation with liraglutide dose.
AEs and MESI
AEs were analyzed using the FAS population. In total, 653 patients (20.7%) experienced at least one AE during the study period, with 458 patients (14.5%) experiencing an AE possibly related to liraglutide. AE categories affecting at least 1.0% of the population are listed in Table 4 . There were six serious AEs involving digestive pathologies (one abdominal pain, two diarrhea, two nausea, and one vomiting). There were eight MESI related to pancreatic 
DISCUSSION
The EVIDENCE study was a prospective, observational study that aimed to assess conditions for prescription, maintenance dose, effectiveness, and safety of liraglutide in routine clinical practice in France. To minimize the limitations associated with the design of an observational study, physicians were chosen at random from a large sample and the number of patients recruited by each physician was limited to prevent a cluster effect. In total, 992 physicians at 992 sites in mainland France participated in the study. Therefore, this study can be considered representative of the national profile. Throughout the study, all contact between the sites and the sponsor went through the research organization to avoid bias in the delivery of routine care, and quality control was applied to each step of data handling, ensuring the correctness of all data, specifically regarding safety reporting. As this was an observational study, with no control group, the results are indicative of certain combinations and cannot give rise to cause-and-effect relationships. Furthermore, the complete data are not available for analysis for all patients, as any missing data were not replaced.
In the EVIDENCE study, the main motivation for physicians to prescribe liraglutide was to improve glycemic control. of patients across the six LEAD studies) [2] [3] [4] [5] [6] [7] [8] 14] . Taken together, this may suggest that liraglutide was initiated later in the disease course in the EVIDENCE study than in the LEAD studies. Indeed, the mean duration of diabetes for patients was 9.7 years in the EVIDENCE study and between 6.5 and 9.4 years in the LEAD studies [2] [3] [4] [5] [6] [7] [8] . One possible explanation for this is related to the guidelines available during the course of the EVIDENCE study that recommended the use of GLP-1RAs as second-line therapy [15] . Furthermore, 15.6% of patients were treated with insulin prior to liraglutide introduction in the EVIDENCE study, while this was not permitted in the LEAD studies [2] [3] [4] [5] [6] [7] [8] Mean HbA 1c reduction, amounting to -1.0%, at the end of the EVIDENCE study, was clinically relevant and compared well with that in the LEAD RCTs (-0.8% to -1.5%) [2] [3] [4] [5] [6] [7] [8] and other real-world studies (-0.9% to -1.6%) [16] [17] [18] . Furthermore, liraglutide was associated with optimal glycemic control (HbA 1c \7.0%) in *30.0% of patients after 2 years of treatment, while only 9.8% of patients had HbA 1c \7.0% at baseline. The proportion of patients achieving optimal glycemic control in the EVIDENCE study is almost identical to results from a recent 26-week UK-based real-world study (29.3%) [16] and only slightly below the *35.0% to *45.0% reported after 26 weeks of treatment in the LEAD RCTs, which shows liraglutide's effectiveness under standard conditions for use [2-5, 7, 8] . When comparing data from the EVIDENCE study with that from the LEAD-3 extension study (18 months in duration), a greater difference in patients achieving optimal glycemic control (HbA 1c \7.0%) is apparent, i.e., *30.0% in EVIDENCE vs. *53.0-58.0% in the LEAD-3 extension study [19] . However, it is possible that the proportion of patients achieving optimal glycemic control in the LEAD-3 extension study is influenced by survivor bias.
Real-world data demonstrate that most T2D patients starting GLP-1RA therapy have a high BMI [20] , and previous studies have shown that liraglutide is associated with weight loss [21, 22] . Moreover, a recent study showed that, across the LEAD studies, higher initial BMI was associated with slightly greater weight loss with liraglutide [14] . Therefore, unsurprisingly, the desire for improved weight control was an important motivation for physicians to prescribe liraglutide in the EVIDENCE study. In total, 95.2% of patients involved in the EVIDENCE study had a baseline BMI C25 kg/m 2 and, as reported in RCTs [2] [3] [4] [5] [6] [7] [8] and other real-world studies with liraglutide [16] [17] [18] , the reductions in both weight and BMI seen throughout the EVIDENCE study were statistically significant. Although the impact of such weight loss in T2D remains to be demonstrated in terms of prognosis, this trend may be enough to at least improve patient quality of life.
Throughout the study, the most commonly prescribed oral antidiabetic treatments remained stable with the introduction of liraglutide. However, there was a reduction in the use of DPP-4 inhibitors from 40.1% to 9.7%. This may be expected, as data from an open-label extension study demonstrate the switch from DPP-4 inhibitor to liraglutide to be beneficial, both in terms of glycemic and weight control [23] . Moreover, liraglutide is not indicated for use in combination with DPP-4 inhibitors [12] , and combinations of incretin-based therapies are not well studied to date and the theoretical benefits appear to be relatively limited [24] . Finally, it is not currently known whether there may be an [17] .
Throughout the study, even though the use of SUs and glinides remained stable and the use of insulin increased, the percentage of patients suffering at least one hypoglycemic episode (during the 4 weeks of preceding visits) decreased from 6.9% (baseline measure) to 4.4% and only nine patients experienced a severe hypoglycemic episode during the entire 2 years of follow-up. To put this into perspective, 11 patients experienced a severe hypoglycemic episode during the 4 weeks preceding inclusion in the study. All patients who experienced a severe hypoglycemic episode were also being treated with both biguanides and SUs or with insulin and glinides. Therefore, it is likely that liraglutide was not the cause of the severe hypoglycemic episodes, and data from the LEAD-3 trial demonstrated no cases of severe hypoglycemia when liraglutide was used as monotherapy [6] . However, with the lack of a control arm in the EVIDENCE study, it is difficult to conclusively evaluate this.
The most frequently reported AE type in this study was classified as belonging to gastrointestinal (GI) disorders, and the frequency reported (10.9%) was similar to that reported in another real-world study (11.4%) [17] . However, this occurrence is considerably lower than that observed with liraglutide in the LEAD RCTs (*33.0% to *56.0%) [2] [3] [4] [5] [6] [7] [8] . This may be due to the less controlled nature of safety reporting in this observational study which is a well-known phenomenon in non-RCTs [25] . However, it may also be possible that a prolonged dose escalation period in the EVIDENCE study may have contributed to this observation.
Based only on very limited data [26] [27] [28] [29] [30] , some researchers have suggested that therapy with GLP-1RAs may increase the risk of pancreatitis [31, 32] . During this study, there were four cases (0.1%) of acute pancreatitis, which is in agreement with the current SmPC for liraglutide (\0.2%) [12] . The incidence of acute pancreatitis in this study was 0.8 cases per 1000 patient-years, which compares well with a rate of 1.6 cases per 1000 patient-years reported in a recent meta-analysis of 18 clinical trials involving liraglutide [33] , and is less than the background incidence (4.2 cases per 1000 patient-years) in people with T2D [34] .
This finding also relates well to another recent study, which suggests that the use of incretin-based drugs appears not to be associated with an increased risk of acute pancreatitis [35] 
